Do we need a vaccine against chikungunya?

Pathogens and Global Health

Volumn 109, Issue 4, 2015, Pages 170-173

  Rezza, Giovanni ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Chikungunya virus; R D; Vaccine

Indexed keywords

CHIKUNGUNYA VACCINE; DNA VACCINE; GLYCOPROTEIN E2; LIVE VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE; VIRUS ANTIBODY;

ANTIBODY DETECTION; ANTIBODY TITER; ARTHRALGIA; CHIKUNGUNYA; CHIKUNGUNYA VIRUS; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEADACHE; HUMAN; IMMUNITY; IMMUNOGENICITY; INJECTION SITE REACTION; INVESTMENT; MALAISE; MARKETING; MYALGIA; NAUSEA; NONHUMAN; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VACCINATION; VIREMIA; VIRUS INFECTIVITY; VIRUS TRANSMISSION; ANIMAL; CHIKUNGUNYA FEVER; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DISEASE OUTBREAKS; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH; IMMUNOLOGY; MOUSE; PUBLIC-PRIVATE PARTNERSHIP;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DISEASE OUTBREAKS; FINANCING, GOVERNMENT; GLOBAL HEALTH; HUMANS; MICE; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; VACCINATION; VACCINES, ATTENUATED;

EID: 84937956410     PISSN: 20477724     EISSN: 20477732     Source Type: Journal    
DOI: 10.1179/2047773215Y.0000000017     Document Type: Review

References (37)

1. Pialoux G, Gauzere B-A, Jaureguiberry S, Strobel M. Chikungunya, an epidemic arbovirosis. Lancet. 2007; 7: 319-27.
2. Rezza G. Dengue and chikungunya: long-distance spread and outbreaks in naïve areas. Pathog Glob Health. 2014; 108: 349-55.
3. Zuckerman AJ, Banatvala JE, Pattison JR, Griffiths PD, Schaub BD. Principle and practice of clinical virology. 5th edn. West Sussex, England: J Wiley & Sons, Ltd; 2005.
4. Ross RW. The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic. J Hyg (Lond). 1956; 54: 177-91.
5. World Health Organization. Chikungunya and dengue, south-west Indian Ocean. Wkly Epidemiol Rec. 2006; 81: 105-16.
6. Charrel RN, de Lamballerie X, Raoult D. Chikungunya outbreaks-the globalization of vectorborne diseases. N Engl J Med. 2007; 356: 769-71.
7. Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli AC, Panning M, et al. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet. 2007; 370: 1840-6.
8. Yergolkar PN, Tandale BV, Arankalle VA, Sathe PS, Sudeep AB, Gandhe SS, et al. Chikungunya outbreaks caused by African genotype, India. Em Infect Dis. 2006; 12: 1580-3.
9. Parola P, de Lamballerie X, Jourdan J, Rovery C, Vaillant V, Minodier P, et al. Novel chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg Infect Dis. 2006; 12: 1483-99.
10. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog. 2007; 3(12): e201.
11. Vazeille M, Moutailler S, Coudrier D, Rousseaux C, Khun H, Huerre M, et al. Two chikungunya isolates from the outbreak of La Reunion (Indian Ocean) exhibit different patterns of infection in the mosquito. Aedes albopictus. Plos One. 2007; 2(11): e1168.
12. Kumar NP, Joseph R, Kamaraj T, Jambulingam P. A226V mutation in virus during the 2007 chikungunya outbreak in Kerala, India. J Gen Virol. 2008; 89: 1945-8.
13. Cassadou S, Boucau S, Petit-Sinturel M, Huc P, Leparc-Goffart I, Ledrans M. Emergence of chikungunya fever on the French side of Saint Martin island, October to December 2013. Euro Surveill. 2014; 2013; 19(13): pii520752-5.
14. Leparc-Goffart I, Nougairede A, Cassadou S, Prat C, de Lambellerie X. Chikungunya in the Americas. Lancet. 2014; 383: 514.
15. Van Bortel W, Dorleans F, Rosine J, Blateau A, Rousset D, Matheus S, et al. Chikungunya outbreak in the Caribbean region, December 2013 to March 2014, and the significance for Europe. Euro Surveill. 2014; 19(13): pii520759-69.
16. Harrison VR, Eckels KH, Bertelloni PJ, Hampton C. Production and evaluation of a formalin killed chikungunya vaccine. J Immunol. 1971; 107: 643-7.
17. HokeCHJr, Pace-Templeton J, Pittman P, MalinoskiFJ, GibbsP, Ulderich T, et al. USmilitary contributionto the global response to pandemic chikungunya. Vaccine. 2012; 30: 6713-20.
18. Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg. 2000; 62: 681-5.
19. McClain DJ, Pittman PR, Ramsburg HH, Nelson GO, Rossi CA, Mangiafico JA, et al. Immunologic intereference from sequential administration of live attenuated alphavirus vaccine. J Infect Dis. 1998; 177: 634-41.
20. Turell MJ, Malinoski FJ. Limited potential for mosquito transmission of a live, attenuated chikungunya virus vaccine. J Trop Med Hyg. 1992; 47: 98-103.
21. Gorchakov R, Wang E, Leal G, Forrester NL, Plante K, Rossi SL, et al. Attenuation of chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein. J Virol. 2012; 86: 6084-6.
22. Weaver SC, Onorio JE, Livengood JA, Chen R, Stinchcomb DT. Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines. 2012; 11: 1087-101.
23. Powers AM. Chikungunya virus control: is a vaccine on the horizon? Lancet. 2014; 384: 2008-9.
24. Singh P, Chhabra M, Mittai V, Sharma P, Rizvi MA, Chauhan LS, et al. Current research and clinical trials for a vaccine against chikungunya virus. Vaccine. 2013; 3: 35-46.
25. Wang E, Volkova E, Adams AP, Forrester N, Xiao SY, Frolov I, et al. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine. 2008; 26: 5030-9.
26. Pedersen CE, Robinson DM, Cole FE. Isolation of the vaccine strain of Venezuelan equine encephalomyelitis virus from mosquitoes in Louisiana. Am J Epidemiol. 1972; 95: 490-6.
27. Plante K, Wang E, Partidos CD, Weger J, Gorchakov R, Tsetsarkin K, et al. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog. 2011; 7: e1002142.
28. Hallengärd D, Kakoulidou M, Lulla A, Kümmerer BM, Johansson DX, Mutso M, et al. Novel attenuated chikungunya vaccine candidate elicit protective immunity in C57BL/6 mice. J Virol. 2014; 88: 2858-66.
29. Roy CJ, Adams AP, Wang E, Plante K, Gorchakov R, Seymour RL, et al. Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. J Infect Dis. 2014; 209: 1891-9.
30. Muthumani K, Lankaraman KM, Laddy DJ, Sundaram SG, Chung CW, Sako E, et al. Immunogenicity of novel consensus-based DNA vaccines aganist chikungunya virus. Vaccine. 2008; 26: 5128-34.
31. Mallilankaraman K, Shedlock DJ, Bao H, Kawalekar OU, Fagone P, Ramanathan AA, et al. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis. 2011; 5: e928.
32. Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet. 2014; 384: 2046-52.
33. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, et al. A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection. Nature Med. 2010; 16: 334-9.
34. FDA, CFR-Code of Federal Regulations Title 21, 'Food and drugs', Vol. 5. [Revised as of April 1, 2014. Cite: 21CFR214] 2014.
35. Andre FE. How the research-based industry approaches vaccine development and establishes priorities. Dev Biol (Basel). 2002; 110: 25-9.
36. Pronker ES, Weenen TC, Commandeur H, Claassen EH, Osterhaus AD. Risk in vaccine research and development quantified. PlosOne. 2013; 8(issue3): e57755.
37. Butler D. Lost in translation. Nature. 2007; 449: 158-9.